Compare Amphastar Pharmaceuticals Inc (AMPH) vs Veritone Inc (VERI) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Veritone (VERI) trades at $1.31, up 4.8% today, with a bullish technical signal despite negative profitability metrics. The company reported Q1 2026 revenue of $90M but missed earnings expectations with a net loss of $111M. Recent business developments include AI partnership expansions with government agencies and new redaction capabilities, while facing multiple securities class action lawsuits alleging improper revenue accounting.

Outlook remains challenging with persistent losses and negative margins, though analyst consensus shows divided sentiment with 46% buy ratings. Key risks include ongoing litigation, execution challenges in achieving profitability, and competitive pressures in the enterprise AI sector. The stock's low price presents speculative potential but requires careful risk assessment.